SARS-CoV-2 assay for BD Veritor Plus gets CE mark

Create PDF

December 2020—BD announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus system has been CE marked to the IVD directive. The test delivers results in 15 minutes and has been authorized by the FDA under an EUA for use by authorized laboratories.

BD expects to produce 12 million SARS-CoV-2 antigen tests per month by March 2021.